The Company’s ordinary issued share capital as at 31 March 2019 was 737 243 810 ordinary shares of £0.10 each which have a primary listing on the LSE in the UK and secondary listings on the JSE in South Africa and the NSX in Namibia. The ordinary share class represents 100% of the Company’s total issued share capital. Further information on the Company’s issued share capital can be found in note 13 to the consolidated financial statements.

There are no known arrangements under which financial rights are held by a person other than the holder of the shares.

Shares acquired through the Company’s share schemes and plans rank equally with the other shares in issue and have no special rights. Further details on the Company’s employee share scheme are included in the Directors’ Remuneration Report.

The Company has no intention to complete a market purchase of its ordinary shares and will not seek this authority at the Company’s annual general meeting on 24 July 2019.


Restrictions on the transfer of company shares

The South African Broad-Based Black Economic Empowerment Act, No. 53 of 2003, as amended, was enacted to establish a legislative framework for the promotion of broad-based black economic empowerment in South Africa and is intended to encourage transformation by including black people in the economy. It covers aspects such as ownership, management control, skills development, enterprise and supplier development and social-economic development. In 2005, Mediclinic International (RF) (Pty) Ltd (previously Mediclinic International Ltd) (“Mediclinic SA”) implemented a black ownership initiative with MP1 Investment Holdings (Pty) Ltd (previously Circle Capital Ventures (Pty) Ltd) (“MP1”) and Phodiso Holdings Ltd (“Phodiso”) (collectively, the “Strategic Black Partners”).

Following the combination of Mediclinic SA with Al Noor Hospitals Group plc in February 2016, the Company entered into arrangements with the Strategic Black Partners to formalise the basis on which the Strategic Black Partners hold their shares in the Company, which are materially the same as the arrangements in existence prior to the combination. The arrangements that originally applied to the holdings of the Strategic Black Partners in relation to their shares in Mediclinic SA before completion of the combination continue to apply to their holdings of shares in the Company.

In the case of the 10 958 206 shares held by MP1 through its subsidiary, Mpilo 1 Newco (RF) (Pty) Ltd (“Mpilo 1”), representing approximately 1.49% of the Company’s issued share capital, disposals of such shares are restricted until 31 December 2019.

The arrangements also contain pre-emptive rights in favour of the Company which provide that, if any of the shares in the Company held by Mpilo 1 are to be offered for sale, the Company will be offered the opportunity to purchase such shares or to nominate another person to purchase such shares, in each case, at a discounted price of approximately 5% to the then market value. Any exercise of a right to purchase such shares by the Company itself would require the approval of its shareholders.

Restrictions on voting rights

The Company’s Articles provide that, unless the Directors determine otherwise, a shareholder shall not be entitled to vote, either personally or by proxy, at any general meeting of the Company or to exercise any other right conferred by membership, if:

  • any call or other sum payable to the Company in respect of that share remains unpaid; or
  • such shareholder, having been duly served with a notice to provide the Company with information under Section 793 of the Act, has failed to do so within 14 days of such notice, for so long as the default continues.


As at year-end, the following shareholders notified the Company, in accordance with Disclosure Guidance and Transparency Rules, of their interest of 3% or more in the Company’s issued share capital:


The Company received no shareholder notifications under the Disclosure Guidance and Transparency Rules between the year-end and the Last Practicable Date.


The Company’s AGM will take place at 15:00 (BST) on Wednesday, 24 July 2019 at Rosewood London Hotel, 252 High Holborn, London WC1V 7EN, UK. All ordinary shareholders have the opportunity to attend and vote, in person or by proxy. All ordinary shareholders have the opportunity to attend and vote, in person or by proxy. The 2019 Notice of AGM can be found on the Investor Relations section of the Company’s website, and is being posted in a separate booklet at the same time as this Annual Report. The notice sets out the business of the meeting and provides explanatory notes on all resolutions. Separate resolutions are proposed in respect of each substantive issue. The AGM is the Company’s principal forum for communication with private shareholders. The Chairman of the Board and the chairpersons of the Board sub-committees, together members of the Group Executive Committee, will be available to answer shareholders’ questions at the meeting and the Directors encourage shareholders to participate at the event.


The Board proposes a final dividend of 4.70 pence per ordinary share for the financial year ended 31 March 2019 for approval by the Company’s shareholders at the AGM to be held on Wednesday, 24 July 2019. The salient dates for the dividend are as follows:

Last date to trade cum dividend (SA register) Tuesday, 11 June 2019
First date of trading ex-dividend (SA register) Wednesday, 12 June 2019
First date of trading ex-dividend (UK register) Thursday, 13 June 2019
Record date for final dividend Friday, 14 June 2019
Shareholder approval at AGM (London) Wednesday, 24 July 2019
Final dividend payment date Monday, 29 July 2019

The Company’s Dividend Policy is dealt with in the Financial Review.

The tax treatment of the dividend for shareholders on the South African register are available on the Company’s website. Details of the dividend access trust established for South African resident shareholders are provided in note 13 of the consolidated financial statements.

The dividends declared by the Company to its ordinary shareholders during the reporting period are summarised below:



The latest share price information can be found on the Company’s website at or through a broker.


Enquiries relating to shareholdings, including notification of change of address, queries regarding the loss of a share certificate and dividend payments should be made to the Company’s registrars:

Shareholders on the Southern African register

South African transfer secretary

Computershare Investor Services (Pty) Ltd
Rosebank Towers, 15 Biermann Avenue,
Rosebank 2196, South Africa
Postal address: PO Box 61051,
Marshalltown 2107, South Africa
Tel: +27 11 370 5000
Fax: +27 11 688 7716

Namibian transfer secretary

Transfer Secretaries (Pty) Ltd
4 Robert Mugabe Avenue, Windhoek, Namibia
Postal address: PO Box 2401, Windhoek, Namibia
Tel: +264 61 227 647
Fax: +264 61 248 531

Shareholders on the UK register

Computershare Investor Services plc
The Pavilions, Bridgwater Road, Bristol, BS99 6ZZ, United Kingdom
Tel: +44 370 703 6022

Lines are open during normal business hours from 08:30–17:30 GMT, Monday to Friday, and charged at the standard rate. Shareholders can use Computershare’s website to check and maintain their records. Details can be found at

Share Dealing Service

Computershare offers a share dealing service which allows UK resident shareholders to buy and sell the Company’s shares. Shareholders can deal in their shares on the Internet or by telephone. Please contact Computershare for more details on this service.


If a few shares are held, which low value makes them difficult to sell, they may be donated to charity through ShareGift, an independent charity share donation scheme. For further details please contact Computershare or ShareGift at telephone number +44 20 7930 3737 or visit their website at